Martin Patricia A. 4

4 · AN2 Therapeutics, Inc. · Filed Mar 23, 2026

AI-generated summary of this filing

Updated Mar 23, 2026

AN2 Therapeutics (ANTX) Director Patricia Martin Receives Repriced Options

What Happened

Patricia A. Martin, a director of AN2 Therapeutics, was the recipient of repriced option awards on March 19, 2026 covering a total of 59,103 underlying shares (three separate award line items: 24,999; 10,362; 23,742). Each repriced option carries an exercise price of $3.91 per share (aggregate strike ≈ $231,093). The filing also reports matching dispositions to the issuer for the same amounts on the same date. These are derivative transactions (options/option-related) rather than open-market buys or sales.

Key Details

Transaction date: March 19, 2026; Form 4 filed March 23, 2026 (timely filing).
Awards: 24,999; 10,362; and 23,742 share equivalents granted (total 59,103).
Dispositions: Matching dispositions to issuer of 24,999; 10,362; and 23,742 (total 59,103) on same date.
Exercise price: $3.91 per share (footnote F1). Option is fully vested (F2). Board approved the repricing on March 19, 2026 (F3).
Shares owned after transaction: Not specified in the provided excerpt of the filing.
Filing timeliness: Filed 4 days after the transaction date; report appears timely (Form 4 is generally due within two business days).

Context

These are derivative/option-related actions—not a simple buy or open-market sale. The filing indicates a repricing of options (approved by the board) and simultaneous dispositions to the issuer; the filing does not show cash proceeds or an open-market sale. The exercise price ($3.91) is the repriced strike and may revert to the original exercise price under conditions described in the footnote (the “Premium End Date” provisions). No 10b5-1 plan, tax-withholding detail, or late-filing flag is indicated in the provided data.

Form 4

Period: 2026-03-19

Director

Transactions

Award
Stock Option (right to buy)
[F1][F3][F2]
2026-03-19+24,999→ 24,999 total
Exercise: $3.91Exp: 2031-04-29→ Common Stock (24,999 underlying)
Disposition to Issuer
Stock Option (right to buy)
[F3][F2]
2026-03-19−24,999→ 0 total
Exercise: $6.60Exp: 2031-04-29→ Common Stock (24,999 underlying)
Award
Stock Option (right to buy)
[F1][F3][F2]
2026-03-19+10,362→ 10,362 total
Exercise: $3.91Exp: 2032-05-11→ Common Stock (10,362 underlying)
Disposition to Issuer
Stock Option (right to buy)
[F3][F2]
2026-03-19−10,362→ 0 total
Exercise: $17.28Exp: 2032-05-11→ Common Stock (10,362 underlying)
Award
Stock Option (right to buy)
[F1][F3][F2]
2026-03-19+23,742→ 23,742 total
Exercise: $3.91Exp: 2033-06-06→ Common Stock (23,742 underlying)
Disposition to Issuer
Stock Option (right to buy)
[F3][F2]
2026-03-19−23,742→ 0 total
Exercise: $5.91Exp: 2033-06-06→ Common Stock (23,742 underlying)

Footnotes (3)

[F1]The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "Premium End Date" (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The "Premium End Date" means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability.
[F2]The option is fully vested.
[F3]On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged.

Signature

/s/ Lucy Day, Attorney-in-Fact for Patricia A. Martin|2026-03-23

1 file